Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy

• Main Authors: Sunkaraneni S (Author), Passarell JA (Author), Ludwig EA (Author), Fiedler-Kelly J (Author), Pitner JK (Author), Grinnell TA (Author), Blum D (Author)
• פורמט: ספר
• יצא לאור: Dove Medical Press, 2017-06-01T00:00:00Z.
• נושאים: article
• גישה מקוונת: Connect to this object online.

Soujanya Sunkaraneni,1 Julie A Passarell,2 Elizabeth A Ludwig,2 Jill Fiedler-Kelly,2 Janet K Pitner,1 Todd A Grinnell,1 David Blum1 1Sunovion Pharmaceuticals Inc., Marlborough, MA, USA; 2Cognigen Corporation (a SimulationsPlus company), Buffalo, NY, USA Purpose: Eslicarbazepine acetate (ESL) is a on...